Literature DB >> 34804879

Extended lymphadenectomy benefits patients with borderline resectable pancreatic head cancer-a single-center retrospective study.

Jing Wang1, Shao-Cheng Lyu1, Ji-Qiao Zhu1, Xian-Liang Li1, Ren Lang1, Qiang He1.   

Abstract

BACKGROUND: Whether standard lymphadenectomy or extended lymphadenectomy should be performed is still under debate during pancreaticoduodenectomy (PD). We aimed to compare their morbidity and mortality rates among patients with pancreatic head cancer (PHC).
METHODS: In this retrospective study, a total of 322 patients were enrolled. According to the scope of intraoperative lymph node dissection, patients were divided into extended lymphadenectomy group (n=120) and standard lymphadenectomy group (n=202). Based on the resectability of the tumor, there were 198 cases of resectable PHC and 124 cases of borderline resectable PHC, respectively, in which further stratified analysis was carried out according to the extent of lymph node dissection.
RESULTS: All patients completed the operation successfully, with a perioperative morbidity rate of 27.9% and mortality rate of 0.9%. As for the overall patients, patients in the extended lymphadenectomy group had higher neutrophil-to-lymphocyte ratio (NLR), longer operation time, more intraoperative blood loss, lymph node dissection and patients with borderline resectable pancreatic head cancer (BRPHC) (P<0.05). The 1-, 2- and 3-year overall survival rates of patients with extended lymphadenectomy and standard lymphadenectomy were 71.9%, 50.6%, 30.0% and 70.0%, 32.9%, 21.5%, respectively (P=0.068). With regards to patients with BRPHC, the number of lymph node dissection in the extended lymphadenectomy group was more (P<0.05), and the 1-, 2- and 3-year overall survival rates of patients with extended lymphadenectomy and standard lymphadenectomy were 60.7%, 43.3%, 27.4% and 43.2%, 17.7%, 17.7%, respectively (P=0.007).
CONCLUSIONS: Patients with BRPHC tended to have vast lymph node metastasis. Extended lymphadenectomy can improve their long-term survival. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Pancreaticoduodenectomy (PD); extended lymphadenectomy; pancreatic head cancer (PHC); prognosis; standard lymphadenectomy

Year:  2021        PMID: 34804879      PMCID: PMC8575711          DOI: 10.21037/gs-21-201

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  50 in total

1.  Portal or superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head carcinoma.

Authors:  Y Murakami; S Satoi; F Motoi; M Sho; M Kawai; I Matsumoto; G Honda
Journal:  Br J Surg       Date:  2015-04-15       Impact factor: 6.939

Review 2.  Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer.

Authors:  C W Michalski; J Kleeff; M N Wente; M K Diener; M W Büchler; H Friess
Journal:  Br J Surg       Date:  2007-03       Impact factor: 6.939

3.  Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?

Authors:  Eileen M O'Reilly; Cristina Ferrone
Journal:  J Clin Oncol       Date:  2020-03-02       Impact factor: 44.544

4.  DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression.

Authors:  Victoria K Xie; Zhiwei Li; Yongmin Yan; Zhiliang Jia; Xiangsheng Zuo; Zhenlin Ju; Jing Wang; Jiawei Du; Dacheng Xie; Keping Xie; Daoyan Wei
Journal:  Clin Cancer Res       Date:  2017-06-28       Impact factor: 12.531

5.  Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material.

Authors:  H Nagai; A Kuroda; Y Morioka
Journal:  Ann Surg       Date:  1986-07       Impact factor: 12.969

6.  Is Pancreatic Head Cancer with Portal Venous Involvement Really Borderline Resectable? Appraisal of an Upfront Surgery Series.

Authors:  Katsuhisa Ohgi; Yusuke Yamamoto; Teiichi Sugiura; Yukiyasu Okamura; Takaaki Ito; Ryo Ashida; Takeshi Aramaki; Katsuhiko Uesaka
Journal:  Ann Surg Oncol       Date:  2017-07-06       Impact factor: 5.344

7.  Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head.

Authors:  O Ishikawa; H Ohhigashi; Y Sasaki; T Kabuto; I Fukuda; H Furukawa; S Imaoka; T Iwanaga
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

8.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

9.  Size of the tumor and other factors influencing prognosis of carcinoma of the head of the pancreas.

Authors:  R Tsuchiya; T Oribe; T Noda
Journal:  Am J Gastroenterol       Date:  1985-06       Impact factor: 10.864

Review 10.  From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.

Authors:  Christopher Nevala-Plagemann; Manuel Hidalgo; Ignacio Garrido-Laguna
Journal:  Nat Rev Clin Oncol       Date:  2019-11-08       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.